Insider · CIK 0001714023
Allan Reine
cfoofficerceodirector
Files at PRME (Prime Medicine, Inc.). First filing May 22, 2025, latest May 22, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$147k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PRME: Prime Medicine, Inc.
PRMEOct 9, 2026 · close 3.99
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 59Moderate | Prime Medicine, Inc. | $147k 125,000 shares | - | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 1, 2025 | PRME Prime Medicine, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -850,000 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +850,000 | - | - | 850,000 | Aug 5, 2025 |
| May 21, 2025 | PRME Prime Medicine, Inc. | POpen-market purchase Common Stock | +125,000 | $1.18 | $147k | 125,000 | May 22, 2025 |
| May 19, 2025 | PRME Prime Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | May 19, 2025 |
| May 8, 2025 | PRME Prime Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 850,000 | May 12, 2025 |
| Dec 5, 2024 | PRME Prime Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 775,000 | Dec 9, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.